NPRL2 gene therapy induces robust antitumor immunity and overcome anti-PD1 resistance through augmenting antigen-presentation and cytotoxic T cells activation in KRAS/STK11 mutant NSCLC in humanized mouse model.
IL-6 signaling drives fibroblast activation in tendinopathy, emerging as a promising therapeutic target for these increasingly prevalent and costly tendon conditions.